Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. officer Sumita Ray reported a derivative PSU exercise and related share sales on August 13, 2026. A block of 18,196 common shares was issued upon settlement of performance stock units, while a matched 18,196 underlying derivative position was exercised and disposed.
To fund tax withholding from this vesting, Ray reported sell-to-cover transactions totaling 8,829 shares, including 2,383 shares at a weighted average price of $29.37 (range $28.97–$29.96), 6,442 shares at a weighted average price of $30.35 (range $29.99–$30.97), and 4 shares at $31.13. The PSUs vest in three equal tranches tied to stock-price targets of $33.00, $38.50, and $44.00 achieved over five consecutive trading days within 24 months of grant; one-third settled on August 13, 2026, with the remaining two-thirds expected to settle upon achievement of the higher targets.
Cue Biopharma, Inc. (CUE) officer Michael Vincent Meluzio reported equity compensation activity and related tax sales. He exercised performance stock units, receiving 13,647 shares of Common Stock, and sold 5,628 shares on August 13, 2026 in block trades used to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. The exercised award represents one-third of a PSU grant tied to stock-price targets, with the remaining two-thirds eligible to settle only if higher share-price hurdles are achieved within a specified performance period.
Cue Biopharma, Inc.’s Chief Executive Officer Shao-Lee Lin reported transactions in Common Stock linked to equity awards. On August 12, 2026, 109,179 performance stock units vested and settled into common shares, representing the first third of a PSU award tied to stock-price hurdles. On August 12–13, 2026, Lin sold an aggregate 58,258 shares at weighted-average prices between $26.50 and $29.87; footnotes state these were block trades executed as “sell-to-cover” transactions to satisfy tax withholding obligations on restricted stock unit vesting and are not discretionary trades. The remaining two-thirds of the PSU award may settle upon achieving closing share prices of $38.50 and $44.00 for five consecutive trading days within 24 months of grant.
A holder of CUE common stock has submitted a notice under Rule 144 describing a proposed sale of up to 58,258 shares of common stock. The shares were acquired as restricted stock units vesting under a registered compensation plan on 08/01/2026. Planned sales include 40,000 shares with an aggregate market value of 1,080,400 and 18,258 shares with an aggregate market value of 515,971, in each case through Maxim Group LLC on the NASDAQ around 08/12/2026 and 08/13/2026, respectively. The issuer has 7,264,414 shares of this class outstanding, providing context for the relative size of the proposed sale.
Cue Biopharma, Inc., a clinical-stage biopharma company, reported a sharply higher net loss while executing major licensing and financing transactions for the quarter and six months ended June 30, 2026. Collaboration revenue rose to $7.9 million for the quarter and $13.6 million year-to-date, compared with $3.0 million and $3.4 million in the prior-year periods, reflecting increased partner activity.
Operating expenses expanded substantially, with general and administrative at $46.6 million and research and development at $49.0 million in the quarter, driven by a $35.1 million upfront license cost for the Ascendant anti-IgE program (CUE-221), elevated stock-based compensation of $23.8 million in the quarter, and other one-time items. A $90.0 million loss on issuance of liability-classified warrants, partly offset by a $24.5 million fair value gain, led to a quarterly net loss of $153.1 million and a six-month loss of $158.2 million.
Cash and cash equivalents were $17.4 million at June 30, 2026, with total assets of $30.7 million and stockholders’ equity of $2.3 million. A July 2026 private placement added approximately $49.8 million of net proceeds, which, together with existing cash, is expected to fund operations for at least 12 months from issuance. A 1-for-30 reverse stock split was effected in April 2026, reducing shares outstanding but increasing the number of authorized and unissued shares.
Cue Biopharma, Inc. reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million a year earlier, driven by a preclinical milestone under its Boehringer Ingelheim collaboration. The company highlighted recent submission of an IND to the FDA for CUE-221 in food allergy and expects Phase 2 data in chronic spontaneous urticaria by the end of the third quarter of 2026. CUE-401 is expected to enter a Phase 1 study with an IND filing anticipated by year-end 2026.
Operating expenses rose sharply due to one-time items: research and development expenses were $49.0 million and general and administrative expenses were $46.6 million, reflecting approximately $20.0 million of CUE-221-related cash payments and $20.0 million of warrant fair-value expense, plus about $23.0 million of strategic transformation costs and $19.7 million of non-cash stock-based compensation. A net non-cash loss of $63.1 million related to liability-classified warrants contributed to a net loss of $153.1 million, versus $8.5 million in 2025. Cash and cash equivalents were $17.4 million as of June 30, 2026, and the company subsequently completed a $50 million private placement. Leadership was expanded with a new Chief Medical Officer and Head of R&D and a new Chief Financial Officer.
Driehaus Capital Management LLC reported beneficial ownership of 292,144 shares of Cue Biopharma, Inc. common stock on a Schedule 13G. This represents 6.96% of the outstanding common stock. All of these shares are reported with shared voting and shared dispositive power; Driehaus reports no sole voting or dispositive power.
The shares are held in fully discretionary accounts for investment advisory clients, including Driehaus Life Sciences Master Fund, L.P., which has rights with respect to more than 5% of Cue Biopharma’s common stock. Clients retain the economic rights to dividends and sale proceeds.
Cue Biopharma, Inc. filed a shelf registration to permit the resale by existing investors of up to 1,505,570 shares of common stock. The registered shares comprise 1,418,070 shares issued in a July 2026 private placement and 87,500 shares issuable upon exercise of outstanding Pre-Funded Warrants with a cash exercise price of $0.001 per share.
The investors originally purchased the securities for aggregate gross proceeds of approximately $50.0 million at $33.21 per share (or $33.209 per Pre-Funded Warrant). Cue Biopharma will not receive proceeds from any resale of these shares, other than nominal cash received upon warrant exercises. As of July 24, 2026, 6,826,387 shares of common stock were outstanding. The company’s independent auditor’s report for 2024–2025 includes an explanatory paragraph regarding the company’s ability to continue as a going concern.